Clinical Trials
2 trialsNCT04023071 2023-10-26
FT516 in Subjects With Advanced Hematologic Malignancies
Fate Therapeutics
Phase 1 Terminated
NCT00625729 2017-12-28
Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
Masonic Cancer Center, University of Minnesota
Phase 1/2 Terminated